| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 20.10 | 5.0% | 7.6% |
| Total Income | 20.10 | 5.0% | 7.6% |
| Expenditure | 45.49 | 35.2% | 4.2% |
| PBT | -21.44 | 46.6% | 17.3% |
| Net Profit | -26.76 | 121.1% | 20.0% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.07 | 121.2% | 22.2% |
Standard BioTools Reports Q2 2026 Financial Results
06 Aug 2026 · 6 Aug, 1:49 am
Summary
Standard BioTools reported second quarter 2026 revenue of $20.1 million, a 7.6% decrease year-over-year, with declines across consumables, instruments, and services. However, gross margins improved to 52.4% from 48.8% in the prior year quarter, driven by productivity gains and reduced warranty expenses. The company also saw a significant 84% improvement in adjusted EBITDA, narrowing the loss to $2.5 million, largely due to a 50% reduction in non-GAAP operating expenses resulting from restructuring actions. The merger with Treeline Biosciences is progressing towards a stockholder vote and is anticipated to close before year-end 2026.
Key Highlights
- 1
Second quarter 2026 revenue was $20.1 million, a decrease of 7.6% year-over-year.
- 2
Consumables revenue for Q2 2026 was $9.4 million, down 10% year-over-year.
- 3
Instruments revenue in Q2 2026 was $5.1 million, down 2% year-over-year.
- 4
Services revenue in Q2 2026 was $5.6 million, down 8% year-over-year.
- 5
Gross margins in the second quarter of 2026 were approximately 52.4%, an improvement from 48.8% in the second quarter of 2025.
- 6
Non-GAAP operating expenses decreased by 50% year-over-year to $13.8 million in the second quarter of 2026.
- 7
Adjusted EBITDA for the second quarter of 2026 showed an improvement of 84% year-over-year, reaching a loss of $2.5 million from a loss of $16.1 million in Q2 2025.
Management Comments
Michael Egholm
We remain on track to close our merger with Treeline Biosciences in 2026, with our previously filed registration statement on Form S-4, our agreement to divest our Mass Cytometry business, and Illumina’s early buyout of contingent payments for $30 million from its acquisition of SomaLogic. We continue to believe this merger is the best path forward to maximize shareholder value, providing exposure to a catalyst-rich, well-capitalized pipeline of potential new therapeutics with significant near and long term value creation opportunities, and we look forward to updating stockholders as we progress toward the vote and closing. While the transaction process continues, our team remains focused on serving our customers. Our continued cost discipline drove an 84% year-over-year improvement in adjusted EBITDA for the second quarter.
Informational and educational content only. Not investment advice.